Teva Pharmaceuticals (Israel)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. IQVIA (France)法国6
2. Teva Pharmaceuticals (United States)美国4
3. Sanofi (France)法国3
4. Rutgers, The State University of New Jersey美国3
5. Teva Pharmaceuticals (Canada)加拿大2
6. Pfizer (United States)美国2
7. Merck & Co., Inc., Rahway, NJ, USA (United States)美国2
8. Sanofi (Canada)加拿大1

按月发文

逐年被引

最新文献

1. 1
   Assessing the Risk of Adverse Maternal and Infant Outcomes Following Prenatal Modafinil Exposure: A French Nationwide Cohort StudyDrug Safety20260
2. 2
   Pregnancy and Infant Outcomes in Women with Multiple Sclerosis Exposed to Glatiramer Acetate Therapy: An Extended 4-Year Safety UpdateDrug Safety20253
3. 3
   Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European CountriesPharmacoepidemiology and Drug Safety20243
4. 4
   Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping reviewPharmacoepidemiology and Drug Safety202423
5. 5
   Overview of global real‐world data sources for pediatric pharmacoepidemiologic researchPharmacoepidemiology and Drug Safety20237
6. 6
   Delayed pregnancy detection and return to fertility with extended levonorgestrel‐containing oral contraceptives: A real world setting cohort studyPharmacoepidemiology and Drug Safety20222
7. 7
   Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and BreastfeedingDrug Safety202220
8. 8
   The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare databasePharmacoepidemiology and Drug Safety20228
9. 9
   Effectiveness of risk minimisation measures for valproate: A cross‐sectional survey among physicians in EuropePharmacoepidemiology and Drug Safety202010
10. 10
    Effectiveness of risk minimisation measures for valproate: A drug utilisation study in EuropePharmacoepidemiology and Drug Safety202020

高被引文献

1. 1
   Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosisExpert Opinion on Drug Safety201631
2. 2
   Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping reviewPharmacoepidemiology and Drug Safety202423
3. 3
   Effectiveness of risk minimisation measures for valproate: A drug utilisation study in EuropePharmacoepidemiology and Drug Safety202020
4. 4
   Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and BreastfeedingDrug Safety202220
5. 5
   Modafinil and the risk of cardiovascular events: Findings from three US claims databasesPharmacoepidemiology and Drug Safety201819
6. 6
   Effectiveness of risk minimisation measures for valproate: A cross‐sectional survey among physicians in EuropePharmacoepidemiology and Drug Safety202010
7. 7
   Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countriesPharmacoepidemiology and Drug Safety20188
8. 8
   The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare databasePharmacoepidemiology and Drug Safety20228
9. 9
   Overview of global real‐world data sources for pediatric pharmacoepidemiologic researchPharmacoepidemiology and Drug Safety20237
10. 10
    Assessment of colistimethate sodium (COLOBREATHE) risk minimization measures implemented in the European Union: A cross‐sectional studyPharmacoepidemiology and Drug Safety20194

主要发表期刊